Literature DB >> 23023713

Pathogenesis of follicular lymphoma.

Robert Kridel1, Laurie H Sehn, Randy D Gascoyne.   

Abstract

The hallmark t(14;18)(q32;q21) in follicular lymphoma (FL) results in constitutive overexpression of the BCL2 protein, allowing B cells to abrogate the default germinal center apoptotic program. Most tumors are characterized by recurrent secondary genetic alterations including genomic gains, losses, and mutations, some providing a growth advantage, including alterations in MLL2, EPHA7, TNFRSF14, and EZH2. The sequence in which these events occur and how they contribute to progression and ultimately to transformation is unclear. Lastly, crosstalk between neoplastic B cells and non-neoplastic immune and stromal cells in the microenvironment plays an important role in sustaining tumor cell growth, cultivating immune privilege, and promoting transformation.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23023713      PMCID: PMC3461914          DOI: 10.1172/JCI63186

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  113 in total

1.  Transformation of follicular lymphoma to diffuse large B-cell lymphoma proceeds by distinct oncogenic mechanisms.

Authors:  Andrew J Davies; Andreas Rosenwald; George Wright; Abigail Lee; Kim W Last; Dennis D Weisenburger; Wing C Chan; Jan Delabie; Rita M Braziel; Elias Campo; Randy D Gascoyne; Elaine S Jaffe; Konrad Muller-Hermelink; German Ott; Maria Calaminici; Andrew J Norton; Lindsey K Goff; Jude Fitzgibbon; Louis M Staudt; T Andrew Lister
Journal:  Br J Haematol       Date:  2007-01       Impact factor: 6.998

2.  Human mesenchymal stem cells isolated from bone marrow and lymphoid organs support tumor B-cell growth: role of stromal cells in follicular lymphoma pathogenesis.

Authors:  Patricia Amé-Thomas; Hélène Maby-El Hajjami; Céline Monvoisin; Rachel Jean; Delphine Monnier; Sylvie Caulet-Maugendre; Thierry Guillaudeux; Thierry Lamy; Thierry Fest; Karin Tarte
Journal:  Blood       Date:  2006-09-19       Impact factor: 22.113

3.  Gene-expression and immunohistochemical study of specific T-cell subsets and accessory cell types in the transformation and prognosis of follicular lymphoma.

Authors:  Annuska M Glas; Laurent Knoops; Leonie Delahaye; Marie José Kersten; Robby E Kibbelaar; Lodewyk A Wessels; Ryan van Laar; J Han J M van Krieken; Joke W Baars; John Raemaekers; Philip M Kluin; Laura J van't Veer; Daphne de Jong
Journal:  J Clin Oncol       Date:  2007-01-02       Impact factor: 44.544

4.  The presence of STAT1-positive tumor-associated macrophages and their relation to outcome in patients with follicular lymphoma.

Authors:  Tomás Alvaro; Marylène Lejeune; Francisca I Camacho; Ma Teresa Salvadó; Lydia Sánchez; Juan F García; Carlos Lopez; Joaquín Jaén; Ramón Bosch; Lluis E Pons; Carmen Bellas; Miguel A Piris
Journal:  Haematologica       Date:  2006-12       Impact factor: 9.941

5.  High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma.

Authors:  Joaquim Carreras; Armando Lopez-Guillermo; Bridget C Fox; Lluis Colomo; Antonio Martinez; Giovanna Roncador; Emili Montserrat; Elias Campo; Alison H Banham
Journal:  Blood       Date:  2006-07-06       Impact factor: 22.113

6.  Number of CD4+ cells and location of forkhead box protein P3-positive cells in diagnostic follicular lymphoma tissue microarrays correlates with outcome.

Authors:  Abigail M Lee; Andrew J Clear; Maria Calaminici; Andrew J Davies; Suzanne Jordan; Finlay MacDougall; Janet Matthews; Andrew J Norton; John G Gribben; T Andrew Lister; Lindsey K Goff
Journal:  J Clin Oncol       Date:  2006-10-10       Impact factor: 44.544

7.  Immunohistochemical patterns of reactive microenvironment are associated with clinicobiologic behavior in follicular lymphoma patients.

Authors:  Tomás Alvaro; Marylène Lejeune; Maria-Teresa Salvadó; Carlos Lopez; Joaquín Jaén; Ramón Bosch; Lluis E Pons
Journal:  J Clin Oncol       Date:  2006-12-01       Impact factor: 44.544

8.  Risk and clinical implications of transformation of follicular lymphoma to diffuse large B-cell lymphoma.

Authors:  Silvia Montoto; Andrew John Davies; Janet Matthews; Maria Calaminici; Andrew J Norton; John Amess; Sarah Vinnicombe; Rachel Waters; Ama Z S Rohatiner; T Andrew Lister
Journal:  J Clin Oncol       Date:  2007-05-07       Impact factor: 44.544

9.  Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study.

Authors:  Michael Herold; Antje Haas; Stefanie Srock; Sabine Neser; Kathrin Haifa Al-Ali; Andreas Neubauer; Gottfried Dölken; Ralph Naumann; Wolfgang Knauf; Mathias Freund; Robert Rohrberg; Klaus Höffken; Astrid Franke; Thomas Ittel; Erika Kettner; Ursula Haak; Ulrich Mey; Christian Klinkenstein; Michael Assmann; Ullrich von Grünhagen
Journal:  J Clin Oncol       Date:  2007-04-09       Impact factor: 44.544

10.  Follicular lymphoma-like B cells in healthy individuals: a novel intermediate step in early lymphomagenesis.

Authors:  Sandrine Roulland; Jean-Marc Navarro; Pierre Grenot; Michèle Milili; Julie Agopian; Bertrand Montpellier; Pascal Gauduchon; Pierre Lebailly; Claudine Schiff; Bertrand Nadel
Journal:  J Exp Med       Date:  2006-10-16       Impact factor: 14.307

View more
  116 in total

Review 1.  Epigenetic dysregulation in follicular lymphoma.

Authors:  Shamzah Araf; Jessica Okosun; Lola Koniali; Jude Fitzgibbon; James Heward
Journal:  Epigenomics       Date:  2015-12-23       Impact factor: 4.778

2.  Genetics of follicular lymphoma transformation.

Authors:  Laura Pasqualucci; Hossein Khiabanian; Marco Fangazio; Mansi Vasishtha; Monica Messina; Antony B Holmes; Peter Ouillette; Vladimir Trifonov; Davide Rossi; Fabrizio Tabbò; Maurilio Ponzoni; Amy Chadburn; Vundavalli V Murty; Govind Bhagat; Gianluca Gaidano; Giorgio Inghirami; Sami N Malek; Raul Rabadan; Riccardo Dalla-Favera
Journal:  Cell Rep       Date:  2014-01-02       Impact factor: 9.423

Review 3.  Genomics of lymphoid malignancies reveal major activation pathways in lymphocytes.

Authors:  Birgit Knoechel; Jens G Lohr
Journal:  J Autoimmun       Date:  2013-07-21       Impact factor: 7.094

4.  Follicular lymphomas: a tapestry of common and contrasting threads.

Authors:  Elaine S Jaffe
Journal:  Haematologica       Date:  2013-08       Impact factor: 9.941

5.  SIGLEC-G deficiency increases susceptibility to develop B-cell lymphoproliferative disorders.

Authors:  Giorgia Simonetti; Maria Teresa Sabrina Bertilaccio; Tania Veliz Rodriguez; Benedetta Apollonio; Antonis Dagklis; Martina Rocchi; Anna Innocenzi; Stefano Casola; Thomas H Winkler; Lars Nitschke; Maurilio Ponzoni; Federico Caligaris-Cappio; Paolo Ghia
Journal:  Haematologica       Date:  2014-05-23       Impact factor: 9.941

Review 6.  Recommendations for Clinical Trial Development in Follicular Lymphoma.

Authors:  Kami Maddocks; Paul M Barr; Bruce D Cheson; Richard F Little; Lawrence Baizer; Brad S Kahl; John P Leonard; Nathan Fowler; Leo I Gordon; Brian K Link; Jonathan W Friedberg; Stephen M Ansell
Journal:  J Natl Cancer Inst       Date:  2016-12-31       Impact factor: 13.506

7.  GeneDive: A gene interaction search and visualization tool to facilitate precision medicine.

Authors:  Paul Previde; Brook Thomas; Mike Wong; Emily K Mallory; Dragutin Petkovic; Russ B Altman; Anagha Kulkarni
Journal:  Pac Symp Biocomput       Date:  2018

8.  Mutations in linker histone genes HIST1H1 B, C, D, and E; OCT2 (POU2F2); IRF8; and ARID1A underlying the pathogenesis of follicular lymphoma.

Authors:  Hongxiu Li; Mark S Kaminski; Yifeng Li; Mehmet Yildiz; Peter Ouillette; Siân Jones; Heather Fox; Kathryn Jacobi; Kamlai Saiya-Cork; Dale Bixby; Daniel Lebovic; Diane Roulston; Kerby Shedden; Michael Sabel; Lawrence Marentette; Vincent Cimmino; Alfred E Chang; Sami N Malek
Journal:  Blood       Date:  2014-01-16       Impact factor: 22.113

9.  Follicular lymphoma t(14;18)-negative is genetically a heterogeneous disease.

Authors:  Dominik Nann; Joan Enric Ramis-Zaldivar; Inga Müller; Blanca Gonzalez-Farre; Janine Schmidt; Caoimhe Egan; Julia Salmeron-Villalobos; Guillem Clot; Sven Mattern; Franziska Otto; Barbara Mankel; Dolors Colomer; Olga Balagué; Vanessa Szablewski; Carmen Lome-Maldonado; Lorenzo Leoncini; Stefan Dojcinov; Andreas Chott; Christiane Copie-Bergman; Irina Bonzheim; Falko Fend; Elaine S Jaffe; Elias Campo; Itziar Salaverria; Leticia Quintanilla-Martinez
Journal:  Blood Adv       Date:  2020-11-24

10.  Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid Malignancies.

Authors:  Romain Guièze; Vivian M Liu; Daniel Rosebrock; Alexis A Jourdain; María Hernández-Sánchez; Aina Martinez Zurita; Jing Sun; Elisa Ten Hacken; Kaitlyn Baranowski; Philip A Thompson; Jin-Mi Heo; Zachary Cartun; Ozan Aygün; J Bryan Iorgulescu; Wandi Zhang; Giulia Notarangelo; Dimitri Livitz; Shuqiang Li; Matthew S Davids; Anat Biran; Stacey M Fernandes; Jennifer R Brown; Ana Lako; Zoe B Ciantra; Matthew A Lawlor; Derin B Keskin; Namrata D Udeshi; William G Wierda; Kenneth J Livak; Anthony G Letai; Donna Neuberg; J Wade Harper; Steven A Carr; Federica Piccioni; Christopher J Ott; Ignaty Leshchiner; Cory M Johannessen; John Doench; Vamsi K Mootha; Gad Getz; Catherine J Wu
Journal:  Cancer Cell       Date:  2019-09-19       Impact factor: 31.743

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.